Mualliflar

  • Jo’rayeva Gulrux Bafoyevna

DOI:

https://doi.org/10.71337/inlibrary.uz.tinnint.118950

Kalit so‘zlar:

Kalit so‘zlar: Metabolik sindrom endotelial disfunktsiya azot oksidi endotelin-1 ICAM-1 VCAM-1 E-selectin mikroangiopatiya ko‘z tomirlari biokimyoviy markerlar oftalmoskopiya.

Annotasiya

 
Annotatsiya.  Ushbu  maqolada  metabolik  sindromga  (MS)  chalingan 
bemorlarda  ko‘z  tomirlari  endoteliysida  yuzaga  keladigan  patologik  o‘zgarishlarni 
baholashda biokimyoviy markerlarning ahamiyati o‘rganildi. Tadqiqotga 12 nafar MS 
tashxisi qo‘yilgan bemor jalb qilindi. Bemorlarning qon zardobida azot oksidi (NO), 
endotelin-1,  VCAM-1,  ICAM-1  va  E-selectin  darajalari  aniqlandi  hamda 
oftalmoskopiya  orqali  ko‘z  tomirlaridagi  mikroangiopatik  o‘zgarishlar  baholandi. 
Natijalar  NO  darajasining  pasayishi  va  boshqa  markerlarning  oshishi  endotelial 
disfunktsiyaning  kuchayganini  ko‘rsatdi.  Bu  holat  mikrosirkulyatsiyaning  buzilishi, 
ko‘z tomirlari devorlarining yallig‘lanishi va o‘tkazuvchanligining ortishi bilan bog‘liq 
ekanligi  aniqlandi.  Biokimyoviy  markerlar  MSda  ko‘z  mikrotomirlari  holatini 
baholashda muhim diagnostik vosita sifatida taklif qilinadi. 


background image

Ta'lim innovatsiyasi va integratsiyasi

https://scientific-jl.com

48-son_1-to’plam_Iyul -2025

273

ISSN:3030-3621

METABOLIK SINDROMDA KO‘Z TOMIRLARI ENDOTELIYSIDAGI

PATOLOGIK O‘ZGARISHLARNI BIOKIMYOVIY MARKERLAR

ORQALI BAHOLASH

Jo’rayeva Gulrux Bafoyevna

Abu Ali ibn Sino nomidagi Buxoro davlat tibbiyot

instituti. Buxoro shahri, O‘zbekiston Respublikasi.

e-mail: jurayeva.gulrux@bsmi.uz


Annotatsiya

. Ushbu maqolada metabolik sindromga (MS) chalingan

bemorlarda ko‘z tomirlari endoteliysida yuzaga keladigan patologik o‘zgarishlarni
baholashda biokimyoviy markerlarning ahamiyati o‘rganildi. Tadqiqotga 12 nafar MS
tashxisi qo‘yilgan bemor jalb qilindi. Bemorlarning qon zardobida azot oksidi (NO),
endotelin-1, VCAM-1, ICAM-1 va E-selectin darajalari aniqlandi hamda
oftalmoskopiya orqali ko‘z tomirlaridagi mikroangiopatik o‘zgarishlar baholandi.
Natijalar NO darajasining pasayishi va boshqa markerlarning oshishi endotelial
disfunktsiyaning kuchayganini ko‘rsatdi. Bu holat mikrosirkulyatsiyaning buzilishi,
ko‘z tomirlari devorlarining yallig‘lanishi va o‘tkazuvchanligining ortishi bilan bog‘liq
ekanligi aniqlandi. Biokimyoviy markerlar MSda ko‘z mikrotomirlari holatini
baholashda muhim diagnostik vosita sifatida taklif qilinadi.

Kalit so‘zlar:

Metabolik sindrom, endotelial disfunktsiya, azot oksidi,

endotelin-1, ICAM-1, VCAM-1, E-selectin, mikroangiopatiya, ko‘z tomirlari,
biokimyoviy markerlar, oftalmoskopiya.

Аннотация.

В данной статье была изучена роль биохимических маркеров

в оценке патологических изменений эндотелия сосудов глаза у пациентов с
метаболическим синдромом (МС). В исследование были включены 12 пациентов
с диагнозом МС. В сыворотке крови больных определяли уровни оксида азота
(NO), эндотелина-1, VCAM-1, ICAM-1 и E-селектина, а также оценивали
микроангиопатические изменения в сосудах глаза с помощью офтальмоскопии.
Результаты показали прогрессирование эндотелиальной дисфункции при
снижении уровня NO и повышении других маркеров. Установлено, что это
состояние связано с нарушением микроциркуляции, воспалением и повышением
проницаемости стенок сосудов глаза. Биохимические маркеры предлагаются в
качестве важного диагностического инструмента при оценке состояния
микрососудов глаза при МС.

Ключевые

слова:

Метаболический

синдром,

эндотелиальная

дисфункция, оксид азота, эндотелин-1, ICAM-1, VCAM-1, E-селектин,
микроангиопатия, сосуды глаза, биохимические маркеры, офтальмоскопия.


background image

Ta'lim innovatsiyasi va integratsiyasi

https://scientific-jl.com

48-son_1-to’plam_Iyul -2025

274

ISSN:3030-3621

Annotation.

In this article, the significance of biochemical markers in assessing

pathological changes in the endothelium of the eye vessels in patients with metabolic
syndrome (MS) was studied. The study involved 12 patients diagnosed with MS. In the
blood serum of patients, the levels of nitric oxide (NO), endothelin-1, VCAM-1,
ICAM-1, and E-selectin were determined, and microangiopathic changes in the eye
vessels were assessed by ophthalmoscopy. The results showed an increase in
endothelial dysfunction with a decrease in the level of NO and an increase in other
markers. It was established that this condition is associated with impaired
microcirculation, inflammation, and increased permeability of the walls of the eye
vessels. Biochemical markers are proposed as an important diagnostic tool for
assessing the state of eye microvessels in MS.

Keywords:

Metabolic syndrome, endothelial dysfunction, nitric oxide,

endothelin-1, ICAM-1, VCAM-1, E-selectin, microangiopathy, ocular vessels,
biochemical markers, ophthalmoscopy.


Kirish.

Metabolik sindrom (MS) — bu bir vaqtning o‘zida bir nechta xavf

omillari: abdominal semizlik, gipertoniya, dislipidemiya va giperglikemiya bilan
kechadigan holatdir. Bu holat mikrotomirlar, xususan, ko‘z tomirlari endoteliysida
strukturaviy va funksional buzilishlarga olib keladi. Endotelial disfunktsiya — bu
tomirlar normal fiziologik holatining buzilishi bo‘lib, yurak-qon tomir, nevrorologik
va oftalmologik asoratlarning ilk bosqichidir. Uni baholashda biokimyoviy markerlar,
ayniqsa azot oksidi (NO), endotelin-1, VCAM-1, ICAM-1, E-selectin muhim rol
o‘ynaydi.

Metabolik sindromga chalingan bemorlarda ko‘z tomirlari endoteliysidagi

o‘zgarishlarni biokimyoviy markerlar asosida baholash va endotelial disfunktsiyaning
erta belgilarini aniqlash.

Materiallar va metodlar.

Tadqiqotda 12 nafar metabolik sindrom tashxisi

qo‘yilgan bemor (6 nafar ayol va 6 nafar erkak) ishtirok etdi. Ishtirokchilarning yoshi
42 dan 63 yoshgacha bo‘lib, ularning barchasida metabolik sindrom IDF (International
Diabetes Federation) mezonlari asosida aniqlangan. Tadqiqot 2025-yilning mart
oyidan may oyigacha bo‘lgan davrda amalga oshirildi. Tanlovga qo‘yilgan asosiy
mezonlar quyidagilardan iborat: metabolik sindrom tashxisining mavjudligi, 40
yoshdan katta bo‘lish, va og‘ir ko‘z kasalliklarining yo‘qligi.

Baholash quyidagi metodlar asosida amalga oshirildi:
1. Klinik va antropometrik ko‘rsatkichlar:
Har bir bemorda tana vazni va bo‘yiga nisbatan tana massasi indeksi (BMI), bel

atrofi o‘lchami va arterial qon bosimi aniqlandi.

2. Biokimyoviy tahlillar:


background image

Ta'lim innovatsiyasi va integratsiyasi

https://scientific-jl.com

48-son_1-to’plam_Iyul -2025

275

ISSN:3030-3621

Endotelial disfunktsiyani baholash uchun quyidagi biokimyoviy markerlar

o‘rganildi:

NO (azot oksidi)

Endotelin-1

VCAM-1 (vascular cell adhesion molecule-1)

ICAM-1 (intercellular adhesion molecule-1)

E-selektin

Bu ko‘rsatkichlar o‘rta vena qonidan olingan namunalar asosida ELISA (ferment

bilan bog‘langan immunosorbent tahlil) usuli yordamida aniqlandi.

3. Ko‘z tomirlari holatini baholash:
Oftalmoskopik tekshiruv orqali bemorlarning ko‘z tubidagi o‘zgarishlar,

xususan gipotonik faza, mikroanevrizmalar mavjudligi va arterio-venulyar (AV) nisbat
baholandi. Bundan tashqari, ko‘z mikrosirkulyatsiyasining yanada aniq tahlili uchun
Doppler ultratovush tekshiruvlari o‘tkazildi.

№ Yos

h

NO

(μmol/L

)

Endotelin

-1

(pg/mL)

VCAM

-1

(ng/mL

)

ICAM-

1

(ng/mL

)

E-

selectin
(ng/mL

)

Ko‘z tomir

holati

1

45

18.2

9.1

782

412

52.3

Mikroanevrizma

+

2

53

16.7

11.3

820

440

60.1

AV torayish

3

58

15.9

12.0

855

470

63.2

Ekssudat +

4

49

17.8

10.5

798

430

58.9

Mikroangiopatiy

a

5

63

14.6

13.1

890

488

65.4

Gemorragik

nuqtalar

6

60

15.2

12.8

872

476

62.1

AV nisbat

buzilishi

7

42

19.1

8.9

750

402

50.7

Normal holatga

yaqin

8

55

16.2

11.7

805

445

59.3

Mikroanevrizma

+

9

48

18.6

9.5

760

410

53.2

AV torayish

1
0

51

17.1

10.9

799

429

57.0

Ekssudat va

shish

1
1

59

15.5

12.5

870

470

61.9

Mikroangiopatiy

a


background image

Ta'lim innovatsiyasi va integratsiyasi

https://scientific-jl.com

48-son_1-to’plam_Iyul -2025

276

ISSN:3030-3621

1
2

62

14.9

13.2

900

490

66.0

Gemorragiyalar

mavjud

Tadqiqot natijalari metabolik sindromli bemorlarda NO darajasi pasayganini,

endotelin-1, VCAM-1, ICAM-1, va E-selectin darajalari esa oshganini ko‘rsatdi. Bu
esa endotelial disfunktsiyaning mavjudligini va tomir devorlarining yallig‘lanish,
spazm va o‘tkazuvchanlikdagi buzilishlar bilan bog‘liqligini anglatadi. Ko‘z
tomirlaridagi mikroangiopatiya va mikroanevrizmalar bilan ushbu markerlar o‘rtasida
kuchli korrelyatsiya kuzatildi.

Biokimyoviy markerlar — ayniqsa NO va endotelin-1 darajalari — ko‘z

tomirlari endoteliysi holatini baholashda erta diagnostik indikator bo‘lib xizmat qiladi.
Metabolik sindromga chalingan bemorlarda ushbu markerlar asosida mikrotsirkulyator
buzilishlarni oldindan aniqlash va profilaktik choralar ko‘rish mumkin.

Adabiyotlar:

1.

Grundy, S. M., Cleeman, J. I., Daniels, S. R., Donato, K. A., Eckel, R. H., Franklin,
B. A., ... & Costa, F. (2005). Diagnosis and management of the metabolic syndrome:
an American Heart Association/National Heart, Lung, and Blood Institute Scientific
Statement. Circulation, 112(17), 2735–2752.

2.

Davignon, J., & Ganz, P. (2004). Role of endothelial dysfunction in atherosclerosis.
Circulation, 109(23_suppl_1), III-27–III-32.

3.

Hadi, H. A. R., & Suwaidi, J. A. (2007). Endothelial dysfunction in diabetes
mellitus. Vascular Health and Risk Management, 3(6), 853–876.

4.

Huang, A. L., Silver, A. E., & Vita, J. A. (2011). Effects of nitric oxide on vascular
function. Current Opinion in Cardiology, 26(4), 379–383.

5.

Kim, J. A., Montagnani, M., Koh, K. K., & Quon, M. J. (2006). Reciprocal
relationships between insulin resistance and endothelial dysfunction. Circulation,
113(15), 1888–1904.

6.

Kowluru, R. A., & Chan, P. S. (2007). Oxidative stress and diabetic retinopathy.
Experimental Diabetes Research, 2007, Article ID 43603.

7.

Gündüz, A., & Yilmaz, G. (2014). Biomarkers of endothelial dysfunction in
metabolic syndrome. Clinical Chemistry and Laboratory Medicine (CCLM),
52(12), 1707–1713.

8.

Wong, T. Y., & Mitchell, P. (2007). The eye in hypertension. The Lancet,
369(9559), 425–435.

9.

Poredos, P., & Jezovnik, M. K. (2013). Endothelial dysfunction and cardiovascular
disease. International Angiology, 32(2), 109–116.

10.

Böger, R. H. (2004). Association of asymmetric dimethylarginine and endothelial
dysfunction. Clinical Chemistry and Laboratory Medicine, 41(11), 1467–1472.


background image

Ta'lim innovatsiyasi va integratsiyasi

https://scientific-jl.com

48-son_1-to’plam_Iyul -2025

277

ISSN:3030-3621

11.

Schalkwijk, C. G., & Stehouwer, C. D. A. (2005). Vascular complications in
diabetes mellitus: the role of endothelial dysfunction. Clinical Science, 109(2), 143–
159.

12.

Lerman, A., & Zeiher, A. M. (2005). Endothelial function: Cardiac events.
Circulation, 111(3), 363–368.

Bibliografik manbalar

Adabiyotlar:

Grundy, S. M., Cleeman, J. I., Daniels, S. R., Donato, K. A., Eckel, R. H., Franklin,

B. A., ... & Costa, F. (2005). Diagnosis and management of the metabolic syndrome:

an American Heart Association/National Heart, Lung, and Blood Institute Scientific

Statement. Circulation, 112(17), 2735–2752.

Davignon, J., & Ganz, P. (2004). Role of endothelial dysfunction in atherosclerosis.

Circulation, 109(23_suppl_1), III-27–III-32.

Hadi, H. A. R., & Suwaidi, J. A. (2007). Endothelial dysfunction in diabetes

mellitus. Vascular Health and Risk Management, 3(6), 853–876.

Huang, A. L., Silver, A. E., & Vita, J. A. (2011). Effects of nitric oxide on vascular

function. Current Opinion in Cardiology, 26(4), 379–383.

Kim, J. A., Montagnani, M., Koh, K. K., & Quon, M. J. (2006). Reciprocal

relationships between insulin resistance and endothelial dysfunction. Circulation,

(15), 1888–1904.

Kowluru, R. A., & Chan, P. S. (2007). Oxidative stress and diabetic retinopathy.

Experimental Diabetes Research, 2007, Article ID 43603.

Gündüz, A., & Yilmaz, G. (2014). Biomarkers of endothelial dysfunction in

metabolic syndrome. Clinical Chemistry and Laboratory Medicine (CCLM),

(12), 1707–1713.

Wong, T. Y., & Mitchell, P. (2007). The eye in hypertension. The Lancet,

(9559), 425–435.

Poredos, P., & Jezovnik, M. K. (2013). Endothelial dysfunction and cardiovascular

disease. International Angiology, 32(2), 109–116.

Böger, R. H. (2004). Association of asymmetric dimethylarginine and endothelial

dysfunction. Clinical Chemistry and Laboratory Medicine, 41(11), 1467–1472.

Schalkwijk, C. G., & Stehouwer, C. D. A. (2005). Vascular complications in

diabetes mellitus: the role of endothelial dysfunction. Clinical Science, 109(2), 143–

Lerman, A., & Zeiher, A. M. (2005). Endothelial function: Cardiac events.

Circulation, 111(3), 363–368.